BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/14/2023 6:01:48 AM | Browse: 242 | Download: 987
 |
Received |
|
2023-09-05 05:22 |
|
Peer-Review Started |
|
2023-09-05 05:24 |
|
First Decision by Editorial Office Director |
|
2023-11-13 09:12 |
|
Return for Revision |
|
2023-11-13 09:12 |
|
Revised |
|
2023-11-25 22:44 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-12-01 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-12-01 06:26 |
|
Articles in Press |
|
2023-12-01 06:26 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-12-11 02:39 |
|
Publish the Manuscript Online |
|
2023-12-14 06:01 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rong-Ting Wu, Ji-Cheng Zhang, Cheng-Nan Fang, Xiao-Yu Qi, Jin-Fei Qiao, Ping Li and Li Su |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Li Su, Doctor, Deputy Director, Department of Chinese Integrative Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, No. 120, Wanshui Road, Shushan District, Hefei 230022, Anhui Province, China. 13615606829@163.com |
| Key Words |
Low-grade myofibroblastic sarcoma; Pancreas; Pembrolizumab; Anlotinib; Immunohistochemistry; Pathology; Case report |
| Core Tip |
Low-grade myofibroblastic sarcoma (LGMS) is a rare spindle cell sarcoma with myofibroblastic differentiation. It is predominantly located in the head, neck, and extremities, whereas less frequently in the abdominal cavity, especially the pancreatic region. LGMS is characterized by a low-grade malignancy and low risk of recurrence and metastases. To date, complete surgical resection remains the primary treatment modality. Despite chemoradiotherapy showing anti-tumor activity for the treatment of postoperative recurrence and metastasis, it remains controversial. Until recently, no effective treatment for LGMS patients intolerant to chemoradiotherapy has been well established. This article aims to explore the new idea of LGMS based on literature obtained from PubMed and a clinical case. |
| Publish Date |
2023-12-14 06:01 |
| Citation |
Wu RT, Zhang JC, Fang CN, Qi XY, Qiao JF, Li P, Su L. Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report. World J Clin Cases 2023; 11(35): 8385-8391 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i35/8385.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i35.8385 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
